Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
АП-Біолік
- Development stage
- Unknown
- Lead developer
- Farmstandart-Biolik
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
АП-Біолік (AP-Biolik) is a monovalent tetanus toxoid vaccine developed and manufactured by Biolik Biopharmaceutical in Ukraine. It contains purified tetanus anatoxin (toxoid) and is indicated for the active immunization of children and adults against tetanus, as well as for emergency prophylaxis following injury. The vaccine works by stimulating the production of specific antitoxic antibodies that neutralize the neurotoxin produced by *Clostridium tetani*. It is formulated as a suspension for injection, typically containing 10 IU per dose, and includes thiomersal as a preservative.
- Brand names
- АП-БіолікAP-Biolik
- Other names
- Tetanus toxoid vaccineTetanus anatoxin
Beyond the preview
Go deeper on АП-Біолік.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on АП-Біолік.